Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials

ESMO Open. 2024 Jul;9(7):103620. doi: 10.1016/j.esmoop.2024.103620. Epub 2024 Jun 18.

Authors

Y Koide¹, T Kodaira²

Affiliations

¹ Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan. Electronic address: [email protected].
² Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan.

No abstract available

Publication types

Editorial
Letter

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use
Brain Neoplasms* / drug therapy
Brain Neoplasms* / radiotherapy
Brain Neoplasms* / secondary
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Breast Neoplasms* / radiotherapy
Chemoradiotherapy / methods
Female
Humans
Immunoconjugates* / pharmacology
Immunoconjugates* / therapeutic use
Necrosis
Radiation Injuries
Receptor, ErbB-2* / metabolism
Trastuzumab / pharmacology
Trastuzumab / therapeutic use

Substances

Immunoconjugates
Receptor, ErbB-2
ERBB2 protein, human
Antineoplastic Agents, Immunological
Trastuzumab